Comparing Ertapenem and Ampicillin-Sulbactam for Intra-Abdominal Infections
Author Information
Author(s): Coccolini Federico, Catena Fausto, Ansaloni Luca, Ercolani Giorgio, Di Saverio Salomone, Gazzotti Filippo, Lazzareschi Daniel, Pinna Antonio D
Primary Institution: St. Orsola-Malpighi University Hospital, Bologna, Italy
Hypothesis
Is a 3-day treatment with Ertapenem as effective and safe as a 3-day treatment with Ampicillin-Sulbactam for localized community-acquired intra-abdominal infections?
Conclusion
The study aims to provide data on the efficacy and safety of a shorter antibiotic treatment duration for intra-abdominal infections.
Supporting Evidence
- Ertapenem is effective against most bacteria associated with community-acquired infections.
- Ampicillin-Sulbactam is a commonly used first-line antibiotic for intra-abdominal infections.
- Shorter antibiotic regimens may reduce the emergence of antibiotic-resistant pathogens.
Takeaway
This study is trying to find out if taking antibiotics for just 3 days is enough to treat certain belly infections instead of the usual longer treatment.
Methodology
The study is a prospective multi-center randomized trial comparing 3-day regimens of Ertapenem and Ampicillin-Sulbactam in patients with localized peritonitis.
Potential Biases
Potential bias may arise from the randomization process and the subjective assessment of treatment outcomes.
Limitations
The study may be limited by the variability in the severity of infections and the reliance on clinical judgment for treatment duration.
Participant Demographics
Adult patients over 18 years requiring surgical intervention for localized intra-abdominal infections.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website